Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17255600 | TRIAZOLE GLYCOLATE OXIDASE INHIBITORS | December 2020 | March 2022 | Allow | 15 | 0 | 1 | Yes | No |
| 17253342 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE | December 2020 | September 2021 | Allow | 9 | 0 | 0 | Yes | No |
| 17039001 | BIOCATALYTIC SYNTHESIS OF CRYPTOPHYCIN ANTICANCER AGENTS | September 2020 | August 2022 | Allow | 22 | 2 | 1 | Yes | No |
| 17043593 | N-HETEROCYCLIC FIVE-MEMBERED RING-CONTAINING CAPSID PROTEIN ASSEMBLY INHIBITOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | September 2020 | May 2022 | Allow | 20 | 1 | 1 | Yes | No |
| 17025644 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | September 2020 | November 2020 | Allow | 2 | 0 | 0 | No | No |
| 16994378 | WATER-BASED EXTRACTION AND PURIFICATION PROCESSES FOR CANNABINOID ACIDS | August 2020 | February 2023 | Allow | 30 | 1 | 0 | Yes | No |
| 16991190 | NOVEL DERIVATIVE OF BETA-APOPICROPODOPHYLLIN AND METHOD OF PREPARING THEREOF | August 2020 | June 2022 | Allow | 22 | 1 | 0 | No | No |
| 16989304 | ABIRATERONE PRODRUGS | August 2020 | August 2022 | Allow | 25 | 0 | 0 | Yes | No |
| 16987721 | PRODRUGS OF KALLIKREIN INHIBITORS | August 2020 | November 2022 | Allow | 27 | 1 | 0 | Yes | No |
| 16985879 | MORPHINAN DERIVATIVES AND USE THEREOF | August 2020 | February 2023 | Abandon | 31 | 1 | 0 | Yes | No |
| 16984152 | MODIFIED AMINO ACIDS | August 2020 | August 2022 | Allow | 24 | 0 | 0 | Yes | No |
| 16965790 | Method for Isolation of Cytisine | July 2020 | August 2022 | Allow | 25 | 0 | 0 | Yes | No |
| 16940430 | PERFLUOROPYRIDINE DERIVED AROMATIC MONOMERS AND PROCESSES OF MAKING AND USING SAME | July 2020 | March 2021 | Allow | 7 | 1 | 0 | Yes | No |
| 16934534 | ZWITTERIONIC CATALYSTS FOR (TRANS)ESTERIFICATION: APPLICATION IN FLUOROINDOLE-DERIVATIVES AND BIODIESEL SYNTHESIS | July 2020 | October 2022 | Allow | 27 | 0 | 1 | Yes | No |
| 16963488 | Solid Forms of Fasoracetam | July 2020 | October 2022 | Allow | 27 | 1 | 1 | No | No |
| 16929694 | SYNTHETIC METHODS FOR PREPARATION OF (S)-(2R,3R,11BR)-3-ISOBUTYL-9,10-DIMETHOXY-2,3,4,6,7,11B-HEXAHYDRO-1H-PYRIDO[2,1,-A]ISOQUINOLIN-2-YL 2-AMINO-3-METHYLBUTANOATE DI(4-METHYLBENZENESULFONATE) | July 2020 | December 2020 | Allow | 5 | 1 | 0 | No | No |
| 16961949 | HALOGENATION OF PYRIDINE DERIVATIVES | July 2020 | October 2022 | Allow | 27 | 1 | 1 | Yes | No |
| 16924346 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | July 2020 | February 2021 | Allow | 7 | 1 | 0 | No | No |
| 16922064 | CRYSTALLINE FORMS OF PLASMA KALLIKREIN INHIBITORS | July 2020 | December 2021 | Allow | 17 | 1 | 1 | Yes | No |
| 16908922 | ORGANIC ELECTROLUMINESCENT COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME | June 2020 | October 2022 | Allow | 27 | 2 | 1 | No | No |
| 16898239 | SOLID FORMS OF A KYNURENINE-3-MONOOXYGENASE INHIBITOR | June 2020 | July 2021 | Allow | 13 | 1 | 0 | No | No |
| 16895221 | PYRAN DERVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | June 2020 | April 2021 | Allow | 10 | 1 | 0 | Yes | No |
| 16768287 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | May 2020 | January 2022 | Abandon | 19 | 1 | 0 | Yes | No |
| 16879810 | ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS | May 2020 | November 2020 | Allow | 6 | 1 | 0 | No | No |
| 16765763 | PROCESS FOR THE PREPARATION OF FLUOPICOLIDE | May 2020 | July 2021 | Allow | 14 | 1 | 0 | No | No |
| 16765826 | DIBUTYLFLUORENE DERIVATIVE AND APPLICATION THEREOF AS PHOTOINITIATOR | May 2020 | September 2022 | Allow | 28 | 0 | 1 | Yes | No |
| 16765806 | 3-OXO-6-HETEROARYL-2-PHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES | May 2020 | October 2022 | Allow | 29 | 2 | 1 | Yes | No |
| 16876966 | PROCESS FOR THE MANUFACTURING OF (6AR,10AR)-7-PROPYL-6,6A,7,8,9,10,10A,11-OCTAHYDRO-[1,3]DIOXOLO[4',5':5,6]BENZO[1,2-G]QUINOLINE AND (4AR,10AR)-1-PROPYL-1,2,3,4,4A,5,10,10A-OCTAHYDRO-BENZO[G]QUINOLINE-6,7-DIOL | May 2020 | June 2021 | Allow | 13 | 1 | 1 | Yes | No |
| 16871333 | SILIBININ 3,3'-THIODIPROPIONIC ACID ESTER WITH HEPATOPROTECTIVE ACTIVITY AND A METHOD OF PREPARING THE SAME | May 2020 | July 2020 | Allow | 3 | 0 | 0 | No | No |
| 16761914 | ORGANIC PHOTOVOLTAIC CELLS AND NON-FULLERENE ACCEPTORS THEREOF | May 2020 | November 2022 | Allow | 30 | 1 | 1 | Yes | No |
| 16070762 | METHOD FOR PREPARING METHIONINE ANALOGUES | May 2020 | November 2021 | Abandon | 40 | 1 | 1 | Yes | No |
| 16866681 | SYNTHESIS OF 5-HYDROXYMETHYLFURFURAL | May 2020 | March 2021 | Allow | 11 | 1 | 0 | No | No |
| 16865855 | PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | May 2020 | March 2021 | Allow | 10 | 1 | 0 | No | No |
| 16865924 | TYK2 INHIBITORS AND USES THEREOF | May 2020 | June 2021 | Allow | 13 | 2 | 0 | Yes | No |
| 15929436 | ACTIVATING PYRUVATE KINASE R | May 2020 | January 2021 | Allow | 8 | 1 | 0 | No | No |
| 16758235 | MITOFLAVOSCINS: TARGETING FLAVIN-CONTAINING ENZYMES ELIMINATES CANCER STEM CELLS (CSCS) BY INHIBITING MITOCHONDRIAL RESPIRATION | April 2020 | August 2021 | Allow | 16 | 2 | 1 | Yes | No |
| 16756576 | EPOXY-OXETANE COMPOUND, METHOD FOR SYNTHESIZING SAME, AND USE OF SAID COMPOUND | April 2020 | November 2020 | Allow | 7 | 0 | 0 | Yes | No |
| 16842744 | METHOD OF SYNTHESIZING (1S,12bS) LACTAM ESTER COMPOUND | April 2020 | February 2021 | Allow | 10 | 1 | 0 | No | No |
| 16652829 | RING-FUSED THIAZOLINO 2-PYRIDONES IN COMBINATION WITH A DRUG AGAINST TUBERCULOSIS | April 2020 | May 2021 | Allow | 14 | 1 | 1 | Yes | No |
| 16834577 | SUBSTITUTED PYRIDINONE-CONTAINING TRYCYCLIC COMPOUNDS, AND METHODS USING SAME | March 2020 | January 2021 | Allow | 10 | 1 | 1 | Yes | No |
| 16831944 | INHIBITORS OF MITOCHONDRIAL FISSION | March 2020 | October 2021 | Allow | 18 | 1 | 1 | Yes | No |
| 16651134 | ELECTRON DONOR, AND METHOD FOR SYNTHESIZING 4, 4'-BIPYRIDINE USING ELECTRON DONOR | March 2020 | March 2021 | Allow | 12 | 1 | 1 | Yes | No |
| 16651049 | OPTICALLY ACTIVE PYRROLIDINE COMPOUND AND METHOD FOR PRODUCING SAME | March 2020 | February 2021 | Allow | 11 | 1 | 0 | Yes | No |
| 16830561 | Polymorphism for Irinotecan Free Base | March 2020 | December 2020 | Allow | 8 | 1 | 0 | No | No |
| 16817749 | SALTS OF A HETEROCYCLIC COMPOUND AND CRYSTALLINE FORMS, PROCESSES FOR PREPARING, THERAPEUTIC USES, AND PHARMACEUTICAL COMPOSITIONS THEREOF | March 2020 | March 2021 | Allow | 12 | 1 | 0 | Yes | No |
| 16818800 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | March 2020 | August 2021 | Allow | 18 | 1 | 0 | No | No |
| 16814320 | HERBICIDAL PYRIDINO-/PYRIMIDINO-THIAZOLES | March 2020 | June 2022 | Allow | 27 | 0 | 0 | No | No |
| 16646050 | BETA-HYDROXY HETEROCYCLIC AMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | March 2020 | January 2022 | Allow | 22 | 1 | 1 | Yes | No |
| 16645525 | PRO-FRAGRANCES AND METHOD OF PREPARATION THEREOF | March 2020 | January 2023 | Abandon | 34 | 1 | 0 | No | No |
| 16645411 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS AND USES THEREOF | March 2020 | January 2021 | Allow | 11 | 1 | 0 | No | No |
| 16645286 | HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA | March 2020 | February 2022 | Allow | 23 | 1 | 1 | Yes | No |
| 16808912 | ABIRATERONE PRODRUGS | March 2020 | June 2020 | Allow | 4 | 0 | 0 | Yes | No |
| 16808246 | DIHYDROCHROMENE DERIVATIVES | March 2020 | July 2020 | Allow | 4 | 0 | 0 | Yes | No |
| 16807218 | 3-PHENYL-2,3,4,8,9,10-HEXAHYDROPYRANO[2,3-F]CHROMENE DERIVATIVE AND METHOD FOR SYNTHESIZING OPTICAL ISOMER THEREOF | March 2020 | November 2020 | Allow | 8 | 1 | 0 | No | No |
| 16803163 | SELECTIVE EP4 RECEPTOR ANTAGONISTIC SUBSTANCE FOR TREATMENT OF CANCER | February 2020 | October 2020 | Allow | 8 | 1 | 0 | Yes | No |
| 16642706 | BIARYLOXY DERIVATIVES AS TTX-S BLOCKERS | February 2020 | April 2021 | Allow | 13 | 1 | 0 | Yes | No |
| 16642817 | THERAPEUTIC INDAZOLES | February 2020 | July 2021 | Allow | 17 | 1 | 0 | Yes | No |
| 16640418 | OCTENDIDINE BASED COMPOUNDS | February 2020 | October 2020 | Allow | 8 | 0 | 0 | No | No |
| 16640264 | ANNULATED GLYCOSIDASE INHIBITORS | February 2020 | May 2022 | Allow | 27 | 2 | 0 | Yes | No |
| 16639895 | PYRIDYLPYRIDONE COMPOUNDS | February 2020 | April 2021 | Allow | 14 | 0 | 0 | Yes | No |
| 16787471 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING AT LEAST ONE OF THE COMPOUNDS | February 2020 | January 2021 | Allow | 11 | 1 | 0 | Yes | No |
| 16783894 | METHOD FOR PRODUCING HETEROCYCLIC COMPOUND | February 2020 | September 2020 | Allow | 7 | 1 | 0 | No | No |
| 16778155 | PRECURSORS FOR RADIOFLUORINATION | January 2020 | April 2021 | Allow | 15 | 1 | 1 | Yes | No |
| 16773720 | HETEROCYCLIC COMPOUND | January 2020 | December 2020 | Allow | 10 | 1 | 0 | No | No |
| 16752076 | KCNQ2-5 CHANNEL ACTIVATOR | January 2020 | December 2020 | Allow | 10 | 1 | 0 | No | No |
| 16744080 | BROMODOMAIN INHIBITORS | January 2020 | October 2020 | Allow | 9 | 1 | 0 | No | No |
| 16630522 | Functionalized Pyridine Carbamates with Enhanced Neuroprotective Activity | January 2020 | February 2022 | Allow | 25 | 1 | 1 | Yes | No |
| 16739544 | PHENYLPIPERAZINE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) MODULATORS AND THEIR USE | January 2020 | December 2020 | Allow | 11 | 1 | 0 | No | No |
| 16715602 | HEPATITIS B ANTIVIRAL AGENTS | December 2019 | October 2020 | Allow | 10 | 1 | 0 | No | No |
| 16713667 | SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF | December 2019 | November 2021 | Allow | 23 | 5 | 0 | Yes | No |
| 16622352 | HYDROGENATION PROCESS FOR PREPARING OXYCODONE HYDROCHLORIDE FROM 14-HYDROXYCODEINONE | December 2019 | October 2020 | Allow | 10 | 1 | 0 | Yes | No |
| 16622713 | PROCESS FOR MAKING ESTERS OF 2,5-FURANDICARBOXYLIC ACID | December 2019 | April 2021 | Allow | 16 | 1 | 1 | Yes | No |
| 16621885 | TINOSTAMUSTINE FOR USE IN TREATING SARCOMA | December 2019 | October 2022 | Allow | 34 | 1 | 0 | No | No |
| 16618518 | USE OF EZH2 INHIBITORS FOR TREATING CANCER | December 2019 | July 2022 | Allow | 31 | 2 | 1 | Yes | No |
| 16694694 | Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases | November 2019 | November 2020 | Allow | 12 | 1 | 0 | Yes | No |
| 16616826 | ANTI-TUMOR EFFECT POTENTIATOR USING NOVEL BIPHENYL COMPOUND | November 2019 | June 2022 | Allow | 31 | 1 | 1 | Yes | No |
| 16687335 | P97 INHIBITORS FOR TREATING CANCER AND NEURODEGENERATIVE DISORDERS | November 2019 | October 2021 | Abandon | 23 | 1 | 0 | No | No |
| 16613514 | INHIBITION OF GAMMA-GLUTAMYLTRANSFERASE AND GLUTATHIONE CATABOLISM TO ENHANCE THE EFFICACY OF NF-KB SIGNALLING PATHWAY INHIBITORS | November 2019 | September 2021 | Abandon | 22 | 1 | 1 | Yes | No |
| 16680359 | 6-AMINOISOQUINOLINE COMPOUNDS | November 2019 | September 2020 | Allow | 10 | 1 | 0 | No | No |
| 16612168 | CRYSTAL OF BENZOFURAN DERIVATIVE FREE BASE AND PREPARATION METHOD | November 2019 | July 2021 | Allow | 20 | 1 | 0 | Yes | No |
| 16605757 | CYCLIC PLASMENYLETHANOLAMINES | October 2019 | December 2021 | Allow | 26 | 1 | 0 | Yes | No |
| 16594344 | SMALL MOLECULE MDM2 PROTEIN DEGRADERS | October 2019 | February 2021 | Allow | 17 | 2 | 1 | Yes | No |
| 16592595 | PROCESS OF MAKING SOMATOSTATIN MODULATORS | October 2019 | September 2020 | Allow | 11 | 1 | 0 | Yes | No |
| 16586498 | S1PR2 ANTAGONISTS AND USES THEREFOR | September 2019 | August 2020 | Allow | 11 | 1 | 0 | No | No |
| 16498870 | SYNTHETIC PROCESSES AND SYNTHETIC INTERMEDIATES | September 2019 | May 2020 | Allow | 7 | 0 | 0 | Yes | No |
| 16580138 | NOVEL METHODS FOR PREPARATION OF SUBSTITUTED PYRIDINES AND RELATED NOVEL COMPOUNDS | September 2019 | May 2021 | Allow | 20 | 1 | 1 | Yes | No |
| 16496961 | NEW CATALYTIC SYSTEM FOR SCALABLE PREPARATION OF INDOXACARB | September 2019 | January 2021 | Allow | 16 | 0 | 1 | Yes | No |
| 16576360 | ACTIVATING PYRUVATE KINASE R | September 2019 | January 2020 | Allow | 4 | 0 | 0 | Yes | No |
| 16574373 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | September 2019 | December 2020 | Abandon | 15 | 1 | 0 | No | No |
| 16568459 | AZAINDOLES AS INHIBITORS OF HPK1 | September 2019 | November 2020 | Allow | 14 | 0 | 1 | Yes | No |
| 16559138 | 5 TO 7 MEMBERED HETEROCYCLIC AMIDES AS JAK INHIBITORS | September 2019 | April 2020 | Allow | 8 | 0 | 0 | No | No |
| 16487939 | PROCESS FOR THE PRODUCTION OF TETRAAMINOBIPHENOL MACROCYCLIC LIGANDS; AND NOVEL TETRAAMINOBIPHENOL MACROCYCLIC LIGANDS | August 2019 | February 2021 | Allow | 18 | 1 | 1 | Yes | No |
| 16543303 | WDR5-MLL1 INHIBITORS AND MODULATORS | August 2019 | May 2020 | Allow | 9 | 0 | 0 | Yes | No |
| 16535139 | PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS | August 2019 | July 2020 | Allow | 11 | 1 | 0 | No | No |
| 16530084 | 6-ALKYNYL-PYRIDINE DERIVATIVES | August 2019 | November 2020 | Abandon | 15 | 1 | 0 | Yes | No |
| 16482100 | PROCESS FOR PREPARING D-GLUCARO-6,3-LACTONE | July 2019 | May 2020 | Allow | 9 | 0 | 0 | No | No |
| 16481569 | NATURAL COMPOUNDS AND FIBROSIS | July 2019 | July 2021 | Allow | 24 | 2 | 1 | Yes | No |
| 16522116 | COMPOUNDS FOR USE IN TREATING KIDNEY DISORDERS | July 2019 | May 2021 | Abandon | 21 | 1 | 1 | Yes | No |
| 16480514 | ETHANE-SULFONATE SALT OF QUINOLINE DERIVATIVE | July 2019 | August 2020 | Allow | 13 | 1 | 0 | Yes | No |
| 16480292 | QUINOLINE COMPOUND, PREPARATION METHOD AND MEDICAL USE THEREFOR | July 2019 | July 2020 | Allow | 12 | 1 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner NORTHINGTON DAVIS, ZINNA.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 66.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner NORTHINGTON DAVIS, ZINNA works in Art Unit 1625 and has examined 1,996 patent applications in our dataset. With an allowance rate of 83.3%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 20 months.
Examiner NORTHINGTON DAVIS, ZINNA's allowance rate of 83.3% places them in the 58% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by NORTHINGTON DAVIS, ZINNA receive 0.83 office actions before reaching final disposition. This places the examiner in the 5% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by NORTHINGTON DAVIS, ZINNA is 20 months. This places the examiner in the 91% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a +0.0% benefit to allowance rate for applications examined by NORTHINGTON DAVIS, ZINNA. This interview benefit is in the 19% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 42.4% of applications are subsequently allowed. This success rate is in the 94% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 80.0% of cases where such amendments are filed. This entry rate is in the 96% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 93% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 95.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 47.7% are granted (fully or in part). This grant rate is in the 41% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 9.1% of allowed cases (in the 93% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 5.2% of allowed cases (in the 83% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.